Melanoma Trial, Recruiting (NCT01772771)

Melanoma Trial, Recruiting NCT01772771 Sponsor: M.D. Anderson Cancer Center Condition: Melanoma

Printed from Voxsanity (voxsanity.com.au) — NCT01772771 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Melanoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with cancer (confirmed by a lab test, scan, or cell sample), or are suspected to have glioma (a type of brain tumor), sarcoma (a type of soft tissue or bone cancer), melanoma (skin cancer), or a blood cancer.
You have a non-cancerous (benign) tumor, and your doctor believes that genetic testing of the tumor could be useful for your care.
You are willing and able to read and sign a consent form agreeing to take part.
You have enough stored tissue samples from a previous biopsy or surgery available at MD Anderson for testing (or new tissue is being collected as part of your care or another study).
You may also be eligible for a special part of the study that tests DNA found in your blood (called "liquid biopsy"), particularly if you are being considered for one of your next two treatment options in a clinical trial.

Who may not be able to join:

There are no specific exclusion criteria listed in the official trial information (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 13 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Funda Meric-Bernstam, M.D. Anderson Cancer Center

Phone: 713-792-6940

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT01772771

Sponsor: M.D. Anderson Cancer Center

Phase: Not Applicable

Status: Recruiting

Condition: Melanoma

Trial contact: 713-792-6940

More information: https://clinicaltrials.gov/study/NCT01772771

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with cancer (confirmed by a lab test, scan, or cell sample), or are suspected to have glioma (a type of brain tumor), sarcoma (a type of soft tissue or bone cancer), melanoma (skin cancer), or a blood cancer.
You have a non-cancerous (benign) tumor, and your doctor believes that genetic testing of the tumor could be useful for your care.
You are willing and able to read and sign a consent form agreeing to take part.
You have enough stored tissue samples from a previous biopsy or surgery available at MD Anderson for testing (or new tissue is being collected as part of your care or another study).
You may also be eligible for a special part of the study that tests DNA found in your blood (called "liquid biopsy"), particularly if you are being considered for one of your next two treatment options in a clinical trial.

Who may not be able to join:

There are no specific exclusion criteria listed in the official trial information (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 13 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

M.D. Anderson Cancer Center

Registry

ClinicalTrials.gov

Start date

1 March 2012

Est. completion

1 March 2032

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Frequency of mutations and co-mutations; Distributions of mutations (including on gene expressions); Database of somatic mutations and clinical characteristics

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov